Subject to any deals the company may do, I see 2 key market cap growth phases ... the first one being realisation of the lower risk near term growth phases which will (I guess) propel the SP to where MR Capital say it should go.
The 2nd phase will hinge on clinical trial results with the time duration of the trials being (maybe) 18 months but I can't be all that certain. One analyst I spoke to believes the company would become a clear takeover target with good results on Stage II trials for anti-adhesion so if that is when we shareholders depart ... depart we will. Realisation of a non-dilutive funding arrangement for the trials would be a defensive tactic in this respect.
It will also take another year to get the OTC products onto European and US shelves.
Missing from the RM Capital analysis is any real perspective on where the MK Elisa may go HOWEVER if there is sufficient data at the ready, generic FDA approval may only take 60 to 90 days. Q2 2013 would be my guestimate.
I agree that Anton's target is very conservative (he says so) but he is selling the biotech's virtues into a clapped out market. At this level he is saying a bird in the hand is worth ....
cheers
CDY Price at posting:
1.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)